Dry AMD Had No Treatment. That May Be Changing.

If you or someone you love has dry age-related macular degeneration, you have probably heard the same thing from every doctor: "There is no treatment for the dry form. We monitor it."

For millions of people, that answer has been the reality for decades. Wet AMD got injections. Dry AMD got waiting.

That may be changing. For the first time, clinical trials are showing that stem cell therapy can meaningfully improve vision in people with advanced dry AMD. One trial reported patients gaining more than 20 letters on the eye chart. That is the difference between barely recognizing faces and reading large print.

Here is what the science actually shows, where the trials stand, and what it means for people living with this condition.

What Is Dry AMD, and Why Has It Been So Hard to Treat?

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people over 50 in the developed world. There is a 25% risk of early AMD and an 8% risk of late AMD in patients over age 75, and those numbers are expected to grow as the population ages.

AMD comes in two forms. Wet AMD involves abnormal blood vessels growing under the retina, and it can be managed with regular injections of anti-VEGF drugs. Dry AMD is far more common, accounting for roughly 85-90% of all AMD cases. It progresses slowly as cells in a critical layer of the retina, called the retinal pigment epithelium (RPE), deteriorate and die.

The RPE is a single layer of cells that sits directly behind your photoreceptors, the cells that detect light. Think of the RPE as a support crew for your vision. These cells nourish the photoreceptors, recycle waste products, and absorb stray light. When RPE cells die, the photoreceptors above them stop working too. The result is a growing patch of vision loss in the center of your visual field. This advanced stage is called geographic atrophy.

The challenge with dry AMD has always been straightforward: once RPE cells are gone, they do not grow back. Drugs cannot regenerate a cell layer that no longer exists. That is why researchers have turned to a fundamentally different approach: replacing the missing cells with new ones grown from stem cells.

What Did the Luxa Biotechnology Trial Find?

The most significant results to date come from Luxa Biotechnology's Phase 1/2a trial, published in Cell Stem Cell in 2025. This was the first clinical trial of RPE stem cell-derived RPE cell transplantation for dry AMD to report efficacy outcomes.

Here is what they did. The researchers took RPE stem cells isolated from the RPE layer of donated human eyes and grew them into mature, post-mitotic RPE cells in the laboratory. These cells, called RPESC-RPE-4W, were then injected beneath the retina of six patients with geographic atrophy in a procedure called subretinal transplantation.

The trial started with a low dose of 50,000 cells per eye. Patients were divided into two groups based on their starting vision: three with worse vision (Group A, averaging about 20/250) and three with better vision (Group B).

The Results

The three patients with worse vision showed the most dramatic improvement. At 12 months, their best corrected visual acuity improved an average of 21.67 letters. To put that in perspective, that is roughly the difference between 20/250 (where you struggle to read the biggest letters on the chart) and 20/80 (where you can read large print and recognize faces).

The three patients with better starting vision improved an average of 3.0 letters at 6 months. That is modest, but these patients had less room to improve because their vision was already relatively preserved.

Importantly, no significant inflammation, tumor formation, or product-related serious adverse events were observed. The positive safety profile allowed the trial to move forward with dose escalation, with 12 additional participants now receiving higher doses of 150,000 and 250,000 cells.

What Other Trials Are Underway?

Luxa is not the only team working on this. Several approaches to RPE replacement are now in active clinical trials, each using a slightly different strategy.

The NIH Autologous iPSC-RPE Trial

The National Eye Institute is running a Phase 1/2a trial (NCT04339764) using a different approach: growing RPE cells from the patient's own blood. Researchers take a blood sample, reprogram those cells into induced pluripotent stem cells (iPSCs), then differentiate them into RPE cells. These cells are grown on a biodegradable scaffold to form a tiny patch, which is surgically placed beneath the retina.

The advantage of this approach is that the cells come from the patient's own body, which dramatically reduces the risk of immune rejection. The disadvantage is complexity. Manufacturing a custom RPE patch for each patient takes months and involves extensive quality control. This trial is currently recruiting up to 20 participants.

The USC Retinal Implant

Researchers at the University of Southern California are developing a hair-thin stem cell implant designed to replace damaged RPE in the macula. Early testing has shown the implant can integrate into the retinal environment, and a new trial is being launched to evaluate safety and efficacy in patients with advanced dry AMD.

Eyestem's Eyecyte-RPE

Eyestem Research is running a Phase 1/2a trial (NCT06394232) testing Eyecyte-RPE, an allogeneic RPE cell product delivered as a subretinal injection. This trial is recruiting across multiple sites and adds another approach to the growing pipeline.

Where Should You Set Your Expectations?

Here is the reality check.

These results are genuinely exciting, but they are early. The Luxa trial involved six patients at the lowest dose. Six. The 21-letter improvement in the worse-seeing group is remarkable, but small numbers mean the findings need to be confirmed in larger groups. That process is underway, but it will take time.

Even if the higher-dose cohorts confirm or exceed these results, regulatory approval is still years away. The FDA requires extensive safety data, and the Luxa trial's primary completion date is December 2026, with longer follow-up ongoing after that.

There are also practical realities. Subretinal surgery is delicate. Not every patient with dry AMD would be a candidate. And stem cell manufacturing for approaches like the NIH's autologous method is time-intensive and expensive. Making these therapies widely available will require solving significant logistical challenges.

But none of that diminishes what has been achieved. For a condition that had zero treatment options, there are now multiple Phase 1/2 trials showing safety and early signs of efficacy. That is a genuine inflection point.

What Does This Mean for You?

If you have dry AMD or geographic atrophy, here is the practical takeaway.

First, keep your regular eye appointments. Early detection of progression matters, and your ophthalmologist needs to track changes over time. If you are interested in clinical trials, talk to your doctor about whether you might be eligible. The Luxa and NIH trials are actively recruiting.

Second, know that the research landscape has fundamentally shifted. Dry AMD is no longer a condition without hope of treatment. The question has moved from "Will there ever be a therapy?" to "How soon, and for which patients?"

Third, take care of the macula you have. Lutein, a carotenoid pigment that concentrates in the macula, plays a key role in protecting the RPE cells and photoreceptors from oxidative damage. A diet rich in leafy greens provides lutein, and many people supplement to ensure adequate intake.

The Bigger Picture

What makes these trials so significant is not just the results. It is the proof of concept. For the first time, we have evidence that you can grow new RPE cells, transplant them into a human eye, and achieve measurable improvement in vision. That was theoretical until very recently.

For people who want to support their macular health as part of a proactive, long-term approach, a targeted eye supplement like Sight Guard is designed to complement your existing care by supporting cellular energy and antioxidant balance in the eye.

The future of dry AMD treatment is no longer empty. And that is worth paying attention to.

References

1. Rao RC, Arduini BL, Borden S, et al. Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: low-dose clinical outcomes. Cell Stem Cell. 2025;32(11):1659-1670.e4.

DOI: 10.1016/j.stem.2025.08.012

2. Ryals RC. RPE replacement therapy for dry AMD: early success in a phase 1/2 clinical trial. Cell Stem Cell. 2025;32(11):1637-1638.

DOI: 10.1016/j.stem.2025.10.007

3. Jha S, Hua F, Dejene R, et al. Development of a manufacturing process for clinical autologous hiPSC-derived retinal pigment epithelium. Adv Exp Med Biol. 2025;1486:165-178.

DOI: 10.1007/978-3-031-97297-3_14

4. Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021;105(3):473-491.

DOI: 10.1016/j.mcna.2021.01.003

5. ClinicalTrials.gov. Phase 1/2a study of RPESC-RPE transplantation for dry AMD. NCT04627428. Sponsor: Luxa Biotechnology.

https://clinicaltrials.gov/study/NCT04627428

6. ClinicalTrials.gov. Autologous transplantation of iPSC-derived RPE for geographic atrophy. NCT04339764. Sponsor: National Eye Institute.

https://clinicaltrials.gov/study/NCT04339764

7. ClinicalTrials.gov. Phase 1/2a study of Eyecyte-RPE for geographic atrophy. NCT06394232. Sponsor: Eyestem Research.

https://clinicaltrials.gov/study/NCT06394232